Eyenovia (NASDAQ:EYEN) Shares Down 17.5%

Eyenovia Inc (NASDAQ:EYEN) traded down 17.5% during trading on Thursday . The stock traded as low as $2.55 and last traded at $2.55, 1,234,876 shares traded hands during mid-day trading. An increase of 657% from the average session volume of 163,042 shares. The stock had previously closed at $3.09.

Several analysts recently commented on the stock. Oppenheimer assumed coverage on shares of Kala Pharmaceuticals in a research note on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Zacks Investment Research upgraded shares of FirstService from a “strong sell” rating to a “hold” rating and set a $110.00 price objective for the company in a research note on Tuesday, June 25th. Finally, HC Wainwright reiterated a “buy” rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th.

The company’s 50 day moving average price is $4.62. The company has a market cap of $33.41 million, a PE ratio of -1.40 and a beta of 1.18.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Analysts anticipate that Eyenovia Inc will post -1.8 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Eyenovia stock. Bank of New York Mellon Corp bought a new position in shares of Eyenovia Inc (NASDAQ:EYEN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned about 0.11% of Eyenovia at the end of the most recent quarter. 10.79% of the stock is currently owned by institutional investors.

About Eyenovia (NASDAQ:EYEN)

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Read More: What are Closed-End Mutual Funds?

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.